Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

Background Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved in the USA for adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and in the European Union for patients ≥26 years with R/R B-ALL. Aft...

Full description

Bibliographic Details
Main Authors: Daniel J DeAngelo, Yi Lin, Roch Houot, Marion Subklewe, Petra C Schuberth, Michael R Bishop, Nicolas Boissel, Dimitrios Tzachanis, Jae H Park, Monique C Minnema, Thibaut Leguay, Mehrdad Abedi, Bijal D Shah, Ryan D Cassaday, Olalekan O Oluwole, Aaron C Logan, Max S Topp, Kristen M O'Dwyer, Martha L Arellano, Maria R Baer, Gary J Schiller, William G Wierda, Patrick J Stiff, Deepa Jeyakumar, Daqin Mao, Sabina Adhikary, Lang Zhou, Rita Damico Khalid, Armin Ghobadia
Format: Article
Language:English
Published: BMJ Publishing Group 2023-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/8/e007118.full

Internet

https://jitc.bmj.com/content/11/8/e007118.full

Similar Items